Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 save search
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Published: 2023-09-28 (Crawled : 17:00) - globenewswire.com
SNY | News | $53.63 1.17% 1.16% 4M
|
Health Technology
|
| O: -1.61%
H: 0.0%
C: 0.0%
BNTX | $108.63 6.47% 6.08% 1.2M
|
Health Technology
|
| O: 0.21%
H: 0.04%
C: -1.27%
covid-19 vaccine health authorization canada
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Published: 2023-09-27 (Crawled : 20:00) - globenewswire.com
GRTS | $1.73 10.9% 9.83% 6.9M
|
Health Technology
|
| O: 21.85%
H: 11.03%
C: 7.59%
covid-19 candidate vaccine contract study
Global COVID-19 Testing Strategic Business Report 2023: Market to Reach $5.8 Billion by 2030, Declining by 16.3% - US and Europe Dominate, Asia-Pacific to Witness Fastest Growth
Published: 2023-09-22 (Crawled : 19:00) - prnewswire.com
AXDX | $5.655 9.59% 8.75% 44K
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $96.85 -1.29% 0.52% 5.1M
|
Health Technology
| Email alert
Add to watchlist
ALT | $2.61 4.4% 4.21% 980K
|
Commercial Services
| Email alert
Add to watchlist
covid-19 europe report business reach global growth market
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
Published: 2023-09-20 (Crawled : 13:00) - globenewswire.com
GOVX | $0.5202 1.48% 1.46% 93K
|
Health Technology
|
| O: -2.42%
H: 2.46%
C: -1.33%
covid-19 conference vaccine
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Published: 2023-09-19 (Crawled : 14:00) - biospace.com/
ARCT | $25.52 0.31% 0.31% 470K
|
Health Technology
|
| O: -0.18%
H: 5.8%
C: 2.92%
covid-19 study
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
Published: 2023-09-19 (Crawled : 13:00) - globenewswire.com
GOVX | $0.5202 1.48% 1.46% 93K
|
Health Technology
|
| O: 0.0%
H: 1.91%
C: -0.28%
covid-19 antibody vaccine
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
COEP | $1.165 8.88% 8.15% 150K
|
|
| O: 10.2%
H: 0.0%
C: -5.56%
dvx201 covid-19 update infection risk trials aml therapeutics
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
Published: 2023-09-13 (Crawled : 13:00) - biospace.com/
ICLR | $246.38 -0.28% -0.28% 540K
|
Health Technology
|
| O: 1.04%
H: 2.23%
C: 1.98%
covid-19 trial
COVID-19 Pandemic Spurs Demand for Personal Care Wipes: Market Expands at 6.3% CAGR, Led by Baby Wipes Segment
Published: 2023-09-13 (Crawled : 01:00) - prnewswire.com
JNJ | News | $155.75 -0.72% -0.03% 7.7M
|
Health Technology
|
| O: 1.05%
H: 0.73%
C: 0.14%
EPC | $36.96 -0.51% 0.0% 590K
|
Consumer Non-Durables
|
| O: -0.33%
H: 0.72%
C: -0.1%
covid-19 care baby market
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.3073 -20.27% -8.85% 0
|
Health Technology
| Email alert
Add to watchlist
SRNEQ | $ 0%
|
n/a
| Email alert
Add to watchlist
covid-19 treatment trial
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
PFE | $33.17 3.37% 0.06% 42M
|
Health Technology
|
| O: -0.12%
H: 0.18%
C: -0.88%
SNY | News | $53.63 1.17% 1.16% 4M
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: 0.0%
BNTX | $108.63 6.47% 6.08% 1.2M
|
Health Technology
|
| O: -0.16%
H: 0.2%
C: -1.33%
covid-19 fda vaccine approval
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
MRNA S | $103.315 3.04% 2.95% 4.2M
|
Health Technology
|
| O: -0.78%
H: 0.42%
C: -0.94%
covid-19 fda vaccine approval
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Initial primary endpoint data anticipated in late 2023 or early Q1 2024
Published: 2023-09-11 (Crawled : 19:00) - biospace.com/
IVVD | $1.73 -2.26% -2.31% 40K
|
Manufacturing
|
| O: 2.86%
H: 7.22%
C: 1.67%
vyd222 covid-19 trial
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
Published: 2023-09-11 (Crawled : 13:30) - globenewswire.com
GOVX | $0.5202 1.48% 1.46% 93K
|
Health Technology
|
| O: 3.34%
H: 0.0%
C: -5.53%
covid-19 vaccine trial
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Published: 2023-09-11 (Crawled : 12:00) - biospace.com/
SVA | $6.47 0%
|
Health Technology
| Email alert
Add to watchlist
covid-19 antibody trial injection
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Published: 2023-09-05 (Crawled : 13:00) - biospace.com/
ARCT | $25.52 0.31% 0.31% 470K
|
Health Technology
|
| O: 6.64%
H: 0.0%
C: 0.0%
arct-154 covid-19 vaccine authorization application therapeutics
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Published: 2023-08-30 (Crawled : 14:00) - globenewswire.com
SNY | News | $53.63 1.17% 1.16% 4M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
BNTX | $108.63 6.47% 6.08% 1.2M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
covid-19 chmp vaccine positive
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
IFRX | $3.03 2.71% 2.64% 34K
|
Health Technology
|
| O: 4.44%
H: 2.75%
C: 2.75%
covid-19 vilobelimab review authorization treatment application
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Published: 2023-08-24 (Crawled : 18:00) - biospace.com/
GILD | $74.95 -0.62% -0.63% 4.2M
|
Health Technology
|
| O: -1.39%
H: 1.15%
C: -1.19%
covid-19 veklury fda treat
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
Published: 2023-08-22 (Crawled : 18:00) - globenewswire.com
SNY | News | $53.63 1.17% 1.16% 4M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
REGN | News | $823.27 -1.35% -1.37% 410K
|
Health Technology
|
| O: 0.52%
H: 0.3%
C: -0.5%
covid-19 antibody agreement therapy
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.